Sanofi (NYSE:SNY) – Research analysts at Jefferies Group cut their FY2016 earnings per share (EPS) estimates for Sanofi in a report released on Thursday. Jefferies Group analyst J. Holford now expects that the firm will post earnings of $2.95 per share for the year, down from their prior estimate of $3.06. Jefferies Group has a “Hold” rating on the stock. Jefferies Group also issued estimates for Sanofi’s FY2017 earnings at $2.93 EPS, FY2018 earnings at $3.17 EPS, FY2019 earnings at $3.60 EPS and FY2020 earnings at $4.06 EPS.
Several other equities research analysts have also recently weighed in on the stock. Zacks Investment Research cut shares of Sanofi from a “hold” rating to a “sell” rating in a research report on Wednesday, August 3rd. TheStreet cut shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Monday, August 22nd. Leerink Swann reissued a “buy” rating on shares of Sanofi in a research report on Sunday, October 9th. Berenberg Bank raised shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Thursday, September 8th. Finally, Piper Jaffray Cos. started coverage on shares of Sanofi in a research report on Friday, September 23rd. They set a “neutral” rating for the company. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $60.50.
Shares of Sanofi (NYSE:SNY) opened at 37.75 on Friday. The stock’s 50 day moving average is $38.65 and its 200 day moving average is $40.40. Sanofi has a 52-week low of $37.20 and a 52-week high of $51.88. The company has a market capitalization of $97.17 billion, a P/E ratio of 21.07 and a beta of 0.98.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Pacad Investment Ltd. acquired a new position in shares of Sanofi during the first quarter valued at about $402,000. BlackRock Institutional Trust Company N.A. purchased a new stake in Sanofi during the first quarter worth $175,000. JPMorgan Chase & Co. raised its stake in Sanofi by 14.0% in the first quarter. JPMorgan Chase & Co. now owns 2,220,531 shares of the company’s stock worth $89,178,000 after buying an additional 272,379 shares in the last quarter. Carnick & Kubik LLC raised its stake in Sanofi by 8.7% in the first quarter. Carnick & Kubik LLC now owns 11,681 shares of the company’s stock worth $469,000 after buying an additional 930 shares in the last quarter. Finally, BB&T Securities LLC raised its stake in Sanofi by 21.4% in the first quarter. BB&T Securities LLC now owns 188,094 shares of the company’s stock worth $7,553,000 after buying an additional 33,182 shares in the last quarter. Institutional investors own 9.42% of the company’s stock.
Sanofi, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and marketing of medicines, including those originating from Genzyme Corporation.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.